Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05564637 · ClinicalTrials.gov registry record · Phase 2
A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT05564637: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT05564637 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 29 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05564637, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out more about the drug treprostinil via inhaler and the mechanisms of why patients with pulmonary arterial hypertension related to Interstitial Lung disease (PAH-ILD) have limitations during exercise. The investigator is studying treprostinil's effect on patients with PAH-ILD during exercise and its effect on their quality of life after using it for 3 months.
Primary Outcome
Cardiac output reserve (Qc) is the difference between the heart's maximum output during exercise and its resting output. This was measured using the direct Fick method (L/min).
Interventions
- DRUG Treprostinil
- DIAGNOSTIC_TEST Right Heart Catheterization (RHC) while exercising
- DIAGNOSTIC_TEST Optional Muscle Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2024-10-30 |
| Phase | Phase 2 |
What the finished NCT05564637 record still lists
NCT05564637 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 3 interventions - of which Treprostinil is the first listed.
NCT05564637 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05564637 about?
NCT05564637 is a clinical study titled "A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension". The purpose of this research study is to find out more about the drug treprostinil via inhaler and the mechanisms of why patients with pulmonary arterial hypertension related to Interstitial Lung disease (PAH-ILD) have limitations during exercise. The investigator is studying treprostinil's effect o...
What is the current status of trial NCT05564637?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2023-03-13. Estimated completion is 2024-10-30.
What interventions are being tested in trial NCT05564637?
The interventions under investigation include: Treprostinil (DRUG), Right Heart Catheterization (RHC) while exercising (DIAGNOSTIC_TEST), Optional Muscle Biopsy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05564637?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05564637's enrollment target sits among peer trials
29 1669th of 2000 higher than 324 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI